Fig. 3: Primary efficacy outcome in all prespecified subgroups. | Nature Medicine

Fig. 3: Primary efficacy outcome in all prespecified subgroups.

From: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Fig. 3

Win ratios were calculated using a non-parametric generalized pairwise comparison within subgroup strata; data are presented as point estimates and 95% CIs with two-sided interaction P values. No adjustments for multiple testing were made. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

Back to article page